Abstract | AIM: SUBJECTS AND METHODS: One hundred patients with infiltrative pulmonary tuberculosis in a phase of decay were examined. The patients were divided into 3 groups. Group 1 received the standard therapy (n = 34); Groups 2 (n = 33) and 3 (n = 33) had additionally daily intravenous dropwise infusions of ascorbic acid (500 mg) (OAO "Novosibkhimpharm") or emoxypin (150 mg) (Moscow Endocrine Plant). The drugs were injected for 10 days. Therapeutic efficiency was evaluated during 12 months. RESULTS: Additional use of ascorbic acid decreased the likelihood of progression of the disease to fibrocavernous tuberculosis and promotes a good completion of 12-month course of therapy providing small posttuberculous changes. The administration of emoxypin contributes to eradication of Mycobacterium tuberculosis, reduces the time of decay cavity closure and a need for surgical treatment of pulmonary tuberculosis. CONCLUSION:
|
Authors | I A Volchegorskiĭ, P N Novoselov, T V Astakhova |
Journal | Terapevticheskii arkhiv
(Ter Arkh)
Vol. 81
Issue 11
Pg. 21-4
( 2009)
ISSN: 0040-3660 [Print] Russia (Federation) |
PMID | 20141008
(Publication Type: English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antitubercular Agents
- Picolines
- Ascorbic Acid
- 6-methyl-2-ethyl-3-hydroxypyridine
|
Topics |
- Adult
- Antitubercular Agents
(therapeutic use)
- Ascorbic Acid
(therapeutic use)
- Drug Therapy, Combination
- Female
- Humans
- Male
- Picolines
(therapeutic use)
- Pulmonary Circulation
(drug effects)
- Pulmonary Fibrosis
(pathology, prevention & control)
- Tuberculosis, Pulmonary
(drug therapy, pathology)
|